[{"NetIncomeLoss_1_Q2_USD":-49301000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1991825.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":21.8,"ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_2_Q2_USD":14141000.0,"Depreciation_2_Q2_USD":4734000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":135266000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_Q2_pure":0.011,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":13692000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q2_USD":300793000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_Q2_pure":0.687,"AccruedLiabilitiesCurrent_0_Q2_USD":13539000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"InterestAndOtherIncome_1_Q2_USD":464000.0,"InterestAndOtherIncome_2_Q2_USD":1102000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q2_USD":86566000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":216000.0,"AssetsCurrent_0_Q2_USD":643729000.0,"OperatingLeaseExpense_2_Q2_USD":6200000.0,"OperatingLeaseExpense_1_Q2_USD":3100000.0,"ShareBasedCompensation_2_Q2_USD":19733000.0,"Assets_0_Q2_USD":1033374000.0,"ProceedsFromContributedCapital_2_Q2_USD":429000.0,"CommonStockSharesIssued_0_Q2_shares":140663755.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":13964000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":6060000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":20502000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":13881186.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":13835989.0,"SellingAndMarketingExpense_1_Q2_USD":23216000.0,"SellingAndMarketingExpense_2_Q2_USD":43820000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":10765000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":20756000.0,"ContractWithCustomerLiability_0_Q2_USD":203195000.0,"OtherNoncashIncomeExpense_2_Q2_USD":7000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":1699000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":140359317.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":139667380.0,"GeneralAndAdministrativeExpense_1_Q2_USD":16066000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q2_USD":50000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":20942000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_Q2_shares":493858.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-2476000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":91131000.0,"CommonStockValue_0_Q2_USD":14000.0,"AccountsReceivableNetCurrent_0_Q2_USD":14174000.0,"LettersOfCreditOutstandingAmount_0_Q2_USD":2100000.0,"MinorityInterest_0_Q2_USD":129000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q2_USD":1699000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":10942000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":153936000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":18.5,"ResearchAndDevelopmentExpense_1_Q2_USD":37800000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":71572000.0,"CostsAndExpenses_2_Q2_USD":167992000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":92067000.0,"CostsAndExpenses_1_Q2_USD":88270000.0,"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":31002000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"IncreaseDecreaseInOtherOperatingCapitalNet_2_Q2_USD":120000.0,"OperatingLeaseLiability_0_Q2_USD":108607000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-415000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-677000.0,"Liabilities_0_Q2_USD":340064000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":103774000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":184186000.0,"OtherAssetsNoncurrent_0_Q2_USD":719000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":423000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":842000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-49716000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-90620000.0,"IncreaseDecreaseInInventories_2_Q2_USD":4549000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":269500000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":4480000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":39824506.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-95458000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":16.38,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_Q2_shares":19626.0,"Goodwill_0_Q2_USD":118972000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.046,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-415000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_Q2_pure":0.683,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-677000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q2_USD":1703000.0,"ContractWithCustomerLiabilityRevenueRecognized_0_Q2_USD":40600000.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":-47883000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":96352000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q2_USD":1699000.0,"RestrictedCashNoncurrent_0_Q2_USD":2138000.0,"PaymentsForProceedsFromTenantAllowance_2_Q2_USD":-5400000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":14184000.0,"LiabilitiesCurrent_0_Q2_USD":116648000.0,"AccountsPayableCurrent_0_Q2_USD":6093000.0,"NetIncomeLoss_2_Q2_USD":-89943000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":75235000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":7067000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_0_Q2_USD":91177000.0,"OperatingLeasePayments_2_Q2_USD":3500000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":9383000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":2950197.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_Q2_pure":0.005,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":693310000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":186324000.0,"AdditionalPaidInCapital_0_Q2_USD":1294506000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":20513000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_Q2_pure":0.671,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":12530000.0,"CommonStockSharesOutstanding_0_Q2_shares":140663755.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":4127000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":60750000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-601555000.0,"PreferredStockValue_0_Q2_USD":null,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":20325000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":43.37,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":83553000.0,"InventoryNet_0_Q2_USD":18612000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":414227000.0,"DebtSecuritiesAvailableForSaleAmortizedCostCurrent_0_Q2_USD":413965000.0,"OperatingIncomeLoss_1_Q2_USD":-49765000.0,"OperatingIncomeLoss_2_Q2_USD":-91045000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":38505000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":76947000.0,"CommonStockSharesAuthorized_0_Q2_shares":340000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1995000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":14098000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":35112000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":6.95,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1033374000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":12961704.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-4174000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":37882000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":119642000.0,"StockholdersEquity_0_Q2_USD":693181000.0,"ProfitLoss_1_Q2_USD":-49301000.0,"ProfitLoss_2_Q2_USD":-89943000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.35,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.64,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":5400000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":857000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":4833000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":103800000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":11249000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":19733000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":8630000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-33742000.0,"Ticker":"ADPT","CIK":"1478320","name":"ADAPTIVE BIOTECHNOLOGIES CORP","OfficialName":"Adaptive Biotechnologies Corporation Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1463975665.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210804"}]